UROGEN PHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.15 USD | +2.39% |
|
+3.06% | -5.67% |
| Sales 2024 * | 99.02M 8.26B | Sales 2025 * | 181M 15.12B | Capitalization | 483M 40.26B |
|---|---|---|---|---|---|
| Net income 2024 * | -126M -10.51B | Net income 2025 * | -62M -5.17B | EV / Sales 2024 * | 4.31 x |
| Net cash position 2024 * | 55.62M 4.64B | Net cash position 2025 * | 277M 23.1B | EV / Sales 2025 * | 1.13 x |
| P/E ratio 2024 * |
-3.94
x | P/E ratio 2025 * |
-8.47
x | Employees | 200 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.65% |
More Fundamentals
* Assessed data
More news
Latest transcript on UroGen Pharma Ltd.
More recommendations
More press releases
| 1 day | +2.39% | ||
| 1 week | +3.06% | ||
| Current month | -5.67% | ||
| 1 month | -5.41% | ||
| 3 months | -11.95% | ||
| 6 months | +27.94% | ||
| Current year | -5.67% |
1 week
13.58
14.85
1 month
12.3715.50
Current year
12.3719.87
1 year
8.6924.13
3 years
4.8524.13
5 years
4.8539.97
10 years
4.8569.57
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 03/19/03 | |
Dong Kim
DFI | Director of Finance/CFO | 47 | 01/21/01 |
Jason Smith
CMP | Compliance Officer | 52 | 09/20/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Arie Belldegrun
CHM | Chairman | 74 | 01/12/01 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 01/17/01 |
Fred Cohen
BRD | Director/Board Member | 67 | 16/17/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 14.15 | +2.39% | 135,619 |
| 25/24/25 | 13.82 | -2.74% | 185,411 |
| 24/24/24 | 14.21 | -2.20% | 97,025 |
| 23/24/23 | 14.53 | +1.11% | 216,766 |
| 22/24/22 | 14.37 | +4.66% | 278,571 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Calendar
03/05/2024
- AUA Innovation Nexus Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.15
USD
Average target price
38.5
USD
Spread / Average Target
+172.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.67% | 483M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- URGN Stock
